GSK: Covid-19 vaccine agreements with Canada

(CercleFinance.com) - Sanofi and GSK announce that they have signed agreements with the government of Canada to supply up to 72 million doses of their adjuvanted Covid-19 vaccine, starting in 2021.
This vaccine is currently being developed.

Both companies operate vaccine manufacturing facilities in Canada that are contributing to the development of a vaccine against Covid-19, supported by their respective global industrial networks.

Sanofi and GSK launched a Phase I/II trial on 3 September. They expect to obtain the first results in early December 2020 and to be in a position to launch a pivotal Phase III trial before the end of the year.


Copyright (c) 2020 CercleFinance.com. All rights reserved.